Bluebird Spins Off Oncology Business As Cell, Gene Therapy Segments Grow Apart
Gene Therapy Focus Opens Partnering, Acquisition Opportunities
Executive Summary
Nick Leschly will become CEO of oncology-focused spinoff, while Andrew Obenshain will help gene therapy-focused bluebird
You may also be interested in...
Finance Watch: 2021 Now Has More IPOs Than 2020, But With $3.2bn Less
Public Company Edition: It took 256 days for 2021 to surpass the 2020 record of 86 biopharma initial public offerings in the US in one year. Also, Procaps raised $115m ahead of its SPAC merger and aTyr and bluebird raised $75m each.
Bluebird Exits Europe, Casting Clouds Over Gene Therapy Commercial Effort
The company will prioritize US market for gene therapies; FDA also placed eli-cel for CALD on clinical hold following a case of MDS.
BMS/Bluebird Ready Abecma, First BCMA-Targeting CAR-T, For Initial Patients
Idecabtagene vicleucel for fifth-line multiple myeloma lags GSK’s BCMA-targeting ADC Blenrep, but it is months ahead of J&J/Legend’s CAR-T. Abecma is BMS’s second CAR-T approval this year.